Synonyms: BGB-290 | BGB290 | compound 139 [PMID: 33264017] | Partruvix®
pamiparib is an approved drug (China (2021))
Compound class:
Synthetic organic
Comment: Pamiparib (BGB-290) is an orally bioavailable, selective poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2) inhibitor [2]. It was developed for antineoplastic potential. PARP inhibition is used to treat tumours with defects in their DNA repair/DNA-damage response (DDR) pathway, such as BRCA 1/2 (BReast CAncer gene 1 and 2) mutations. Pamiparib can cross the blood-brain barrier, offering potential as a treatment for brain tumours [3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Pamiparib was issued its first approval for clinical use in China (April 2021) [1]. It was indicated for the treatment of recurrent/advanced ovarian, fallopian tube or primary peritoneal cancers with germline BRCA mutations. |